The lipid analysis devices are used for measuring elevated plasma cholesterol or triglycerides or low level of high-density lipoprotein (HDL). The determination of blood lipid levels is important for monitoring the risk of cardiovascular disease. Lipid analysis device is used for detection of hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, hyperlipoproteinemia, and tangier disease. Lipid analysis device can be implemented at the clinics or it can be a point-of-care device. Point-of-care device has wider application as compared to clinical analyzers due to its low cost, accuracy, ease of use, and rapidity of producing results. The lipid analysis devices market is propelled by rising incidence of abnormal levels of lipids and technological advancements while factors such as high pricing of clinical based analyzers and stringent as well as time consuming regulatory policies are expected to hamper growth of lipid analysis devices market.
Get The Holistic SAMPLE Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1488
The lipid analysis test results were subjected to many drawbacks during patient handling such as inaccuracy in the results due to improper fasting and medications, human error, and various other factors, which gives false negative or false positive results. Therefore, to overcome such drawbacks, lipid analysis market demands for new technology-based devices, which will propel growth of lipid analysis devices market. According to the American Diabetes Association, heart attack or stroke affect people with diabetes more than twice as often as people without diabetes. Therefore, Polymer Technology Systems Diagnostics, in 2013, introduced CardioChek Plus analyzer at the annual American Association for Clinical Chemistry (AACC), which can be used for analyzing both lipid and glucose levels simultaneously. Furthermore, the CardioChek Plus analyzer system is Wi-Fi enabled and can transmit test results of patients to data collection applications. In 2013, Acon Laboratories, Inc., launched the Mission Cholesterol Monitoring system, which can perform 3 tests; total cholesterol (CHOL), high density lipoprotein (HDL), and triglycerides (TRIG).
Lipid disorder is a medical condition where the patient has elevated levels of plasma cholesterol or triglycerides (TG), or both, or a low high-density lipoprotein (HDL) level, which leads to long-term problems such as atherosclerosis, elevated blood pressure, obesity, and diabetes mellitus. Dyslipidemia is a metabolic syndrome where blood lipid levels are elevated leading to increased risk of coronary heart disease (CHD). For instance, according to Registrar General of India, coronary heart disease led to around 17% of the total deaths in 2001-2003, which increased to around 23% in 2010-2013. According to the Centers for Disease Control and Prevention (CDC), in 2015, high blood cholesterol was the leading cause of death in the U.S. and people with high cholesterol had about twice the risk of heart disease, as compared to people with lower cholesterol level. Such high prevalence of high cholesterol and coronary heart disease globally is expected to propel growth of the lipid analysis device market. Furthermore, increasing awareness of lipid analysis devices especially kits among the population is expected to drive growth of the market.
Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1488